<DOC>
	<DOCNO>NCT02679664</DOCNO>
	<brief_summary>The SAVER pilot randomize , open-label pilot study determine feasibility recruitment . In addition feasibility data , investigator carefully collect clinical data determine rosuvastatin reduce post-thrombotic syndrome ( PTS ) venous thromboembolism ( VTE ) patient . Eligible consent patient develop acute , symptomatic , objectively confirm proximal leg deep vein thrombosis ( DVT ) and/or PE randomize equally allocate 2 trial arm , either treatment group ( rosuvastatin tablet ( 20 mg/day ) control group ( usual care ) . The pilot trial consist 4 study contact 6 month : screening , randomization , telephone follow-up ( 90 day ) , final study visit ( 180 day ) .</brief_summary>
	<brief_title>StAtins Venous Event Reduction Patients With Venous Thromboembolism Pilot Study</brief_title>
	<detailed_description>STUDY DESIGN : The SAVER pilot randomize , open-label pilot study determine feasibility recruitment ( main threat successful completion full SAVER RCT ) . In addition feasibility data , investigator carefully collect clinical data determine rosuvastatin reduce PTS VTE patient . Eligible consent patient develop acute , symptomatic , objectively confirm proximal leg DVT and/or pulmonary embolism ( PE ) randomize equally allocate 1 2 trial arm , either treatment group control group . The pilot trial consist 4 study contact 6 month : screening , randomization , telephone follow-up ( 90 day ) , final study visit ( 180 day ) . DOSE/ROUTE/REGIMEN : Patients randomize 1:1 ratio treatment control group . Treatment Group : The treatment arm receive 20 mg tablet rosuvastatin take orally daily start time randomization completion follow-up 6 month . Control Group : Those control arm follow manner receive study medication . MEASURES AND EVALUATION Screening Visit : Research coordinator pilot site screen patient eligibility maintain detailed log exclude enrolled patient . After provide informed consent , eligibility confirm follow test : lipid profile , A1C test transaminase ( ALT ) level analysis.All eligibility review investigator . Randomization Visit : Randomization conduct use Interactive Web base Randomization System . Medication Diaries dispense participant treatment arm baseline along study medication , At final study visit , study coordinator review medication diary compare pill count indicator compliance . Adverse Events : AEs elicit , monitor record throughout study . The investigator report serious adverse event ( SAEs ) SAVER Trial Office Ottawa , Canada within 24 h awareness .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Symptomatic objectively confirm proximal leg DVT ( trifurcation popliteal vein ) and/or PE ( segmental great ) diagnose last 30 day . 1 . Unable unwilling provide write informed consent ; 2 . â‰¤ 18 year age ; 3 . Currently prescribe statin statin indicated prevention cardiovascular disease ; 4 . Diabetes mellitus prediabetes ; 5 . Contraindication rosuvastatin ; 6 . Life expectancy le 3 month , judge investigator ; 7 . Unstable medical psychological condition would interfere trial participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>